Evidence map›Paper›PMID 35710849›Full record

ArticleThe Journal of infectious diseases2023

Seroepidemiological Reconstruction of Long-term Chikungunya Virus Circulation in Burkina Faso and Gabon.

Jacqueline Kyungah Lim, Valery Ridde, Selidji Todagbe Agnandji, Bertrand Lell, Seydou Yaro, Jae Seung Yang, Damien Hoinard, Scott C Weaver, Jessica Vanhomwegen, Henrik Salje and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. The national burden from O'nyong'nyong and chikungunya viruses in Cameroon.medRxiv : the preprint server for health sciences · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Journal of general virology · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 8 countries.

Jacqueline Kyungah LimInternational Vaccine Institute, Seoul, Republic of Korea.
Valery RiddeMontreal School of Public Health, Montreal, Quebec, Canada.
Selidji Todagbe AgnandjiCentre de Recherches Médicales de Lambaréné, Campus Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Bertrand LellCentre de Recherches Médicales de Lambaréné, Campus Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Seydou YaroCentre Muraz, Bobo-Dioulasso, Burkina Faso.
Jae Seung YangInternational Vaccine Institute, Seoul, Republic of Korea.
Damien HoinardInstitut Pasteur, Paris, France.
Scott C WeaverWorld Reference Center for Emerging Viruses and Arboviruses and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Jessica VanhomwegenInstitut Pasteur, Paris, France.
Henrik SaljeDepartment of Genetics, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-3626-4254
In-Kyu YoonInternational Vaccine Institute, Seoul, Republic of Korea.
International Vaccine Institute · KRCentre de Recherche Médicales de Lambaréné · GAInstitut Pasteur · FRCentre Muraz · BFThe University of Texas Medical Branch at Galveston · USUniversity of Cambridge · GB

Funding

World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
Bill & Melinda Gates FoundationEuropean Research CouncilNIAID NIH HHS R24 AI120942NIH HHS
6 · The paper itself

Abstract

Chikungunya virus (CHIKV) is a major public health concern worldwide. However, infection levels are rarely known, especially in Africa. We recruited individuals from Ouagadougou, Burkina Faso and Lambaréné, Gabon (age range, 1-55 years), tested their blood for CHIKV antibodies, and used serocatalytic models to reconstruct epidemiological histories. In Ouagadougou, 291 of 999 (29.1%) individuals were seropositive, ranging from 2% among those aged <10 years to 66% in those aged 40-55 years. We estimated there were 7 outbreaks since the 1970s but none since 2001, resulting in 600 000 infections in the city, none of which were reported. However, we could not definitively conclude whether infections were due to CHIKV or o'nyong-nyong, another alphavirus. In Lambaréné, 117 of 427 (27%) participants were seropositive. Our model identified a single outbreak sometime since 2007, consistent with the only reported CHIKV outbreak in the country. These findings suggest sporadic outbreaks in these settings and that the burden remains undetected or incorrectly attributed.

Indexed as

Chikungunya FeverChikungunya virusAdolescentAdultBurkina FasoChildChild, PreschoolDisease OutbreaksGabonHumansInfantMiddle AgedYoung AdultAfricaBurkina FasochikungunyaGabonseroepidemiology

Identifiers

PMID35710849
PMCPMC9833428
OpenAlexW4283015067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.